A rare type of renal cell carcinoma. It is a well-circumscribed multicystic mass without solid areas. The inner lining of the cystic structures is composed of clear cells.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding multilocular clear cell renal cell carcinoma is limited due to its rarity, affecting fewer than a few hundred individuals worldwide. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and outcomes. As a result, there is a lack of established guidelines for diagnosis and treatment.
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
There are several orphan drugs designated for MCRCC, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved for other types of renal cell carcinoma. Additionally, there are ongoing developments for 20 orphan-designated drugs, including autologous tumor-derived therapies and various immunotherapies. For more information on clinical trials, you can search ClinicalTrials.gov for updates on research related to MCRCC.
Actionable guidance for navigating care for multilocular clear cell renal cell carcinoma
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding multilocular clear cell renal cell carcinoma is limited due to its rarity, affecting fewer than a few hundred individuals worldwide. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and outcomes. As a result, there is a lack of established guidelines for diagnosis and treatment.
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
There are several orphan drugs designated for MCRCC, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved for other types of renal cell carcinoma. Additionally, there are ongoing developments for 20 orphan-designated drugs, including autologous tumor-derived therapies and various immunotherapies. For more information on clinical trials, you can search ClinicalTrials.gov for updates on research related to MCRCC.
Actionable guidance for navigating care for multilocular clear cell renal cell carcinoma
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding multilocular clear cell renal cell carcinoma is limited due to its rarity, affecting fewer than a few hundred individuals worldwide. This extreme rarity makes it challenging to conduct systematic clinical studies and gather comprehensive data on its clinical features and outcomes. As a result, there is a lack of established guidelines for diagnosis and treatment.
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
There are several orphan drugs designated for MCRCC, including bevacizumab, sorafenib, and temsirolimus, which are FDA-approved for other types of renal cell carcinoma. Additionally, there are ongoing developments for 20 orphan-designated drugs, including autologous tumor-derived therapies and various immunotherapies. For more information on clinical trials, you can search ClinicalTrials.gov for updates on research related to MCRCC.
Actionable guidance for navigating care for multilocular clear cell renal cell carcinoma
To navigate your path forward, consider seeking a specialist in renal oncology with experience in rare kidney cancers. This specialist can provide insights into the latest treatment options and clinical trials. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified for MCRCC, participating in clinical trials may provide access to emerging therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.